INDEMNITY AGREEMENTIndemnity Agreement • March 4th, 2022 • AN2 Therapeutics, Inc. • Pharmaceutical preparations • Delaware
THIS INDEMNITY AGREEMENT (this “Agreement”) dated as of , is made by and between AN2 THERAPEUTICS, INC., a Delaware corporation (the “Company”), and (“Indemnitee”).
LICENSE AGREEMENTLicense Agreement • March 4th, 2022 • AN2 Therapeutics, Inc. • Pharmaceutical preparations • New York
This LICENSE AGREEMENT (the “Agreement”) is entered into as of November 20, 2019 (the “Effective Date”) between AN2 Therapeutics, Inc., a company organized under the laws of Delaware (“AN2”) and having its registered office at [***], and Brii Biosciences Limited, an exempted company organized under the laws of the Cayman Islands (“Brii Bio”), having its registered office at [***].
March 5, 2021 AN2 Therapeutics, Inc Re: Amended and Restated Global Health Agreement Ladies and Gentlemen:AN2 Therapeutics, Inc. • March 4th, 2022 • Pharmaceutical preparations • Delaware
This amended and restated global health agreement (“Global Health Agreement”) is entered into in connection with the commitment by Adjuvant Global Health Technology Fund L.P. and Adjuvant Global Health Technology Fund DE L.P. (together, “Adjuvant”) to purchase and subscribe for 198,333 Series B Preferred Shares of AN2 Therapeutics, Inc., a Delaware corporation (the “Company”) at a price of $35.20404 per share (for a total of $6,999,972.84) (the “Investment”) and pursuant to Adjuvant’s prior subscription of 834,724 Series A Preferred Shares at a price of $5.99 per share (for a total of $4,999,996.76). Adjuvant is making the Investment in particular pursuant to the terms of this Global Health Agreement, the Series B Preferred Stock Purchase Agreement dated March 5, 2021, the Amended and Restated Investors’ Rights Agreement dated March 5, 2021 and the amended and restated certificate of incorporation of the Company approved by the stockholders of the Company on March 4, 2021, each such do
LICENSE AGREEMENTLicense Agreement • March 4th, 2022 • AN2 Therapeutics, Inc. • Pharmaceutical preparations • Delaware
THIS LICENSE AGREEMENT (“Agreement”) is made effective as of the 20th day of November, 2019 (the “Effective Date”), by and between AN2 Therapeutics, Inc., a corporation organized and existing under the laws of Delaware with offices at [***] (“Licensee”) and Anacor Pharmaceuticals, Inc., a corporation organized and existing under the laws of Delaware with offices at [***] (“Anacor”). Licensee and Anacor may, from time-to-time, be individually referred to as a “Party” and collectively referred to as the “Parties”.
AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENTInvestors’ Rights Agreement • March 4th, 2022 • AN2 Therapeutics, Inc. • Pharmaceutical preparations • Delaware
THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of the 5th day of March, 2021, by and among AN2 Therapeutics, Inc., a Delaware corporation (the “Company”), and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor.”
